article

Cytochrome P450 2C19 (abbreviated CYP2C19), a member of the cytochrome P450 mixed-function oxidase system, is involved in the metabolism of xenobiotics in the body. It is involved in the metabolism of several important groups of drugs including many proton pump inhibitors and antiepileptics.

Genetic polymorphism exists for CYP2C19 expression, with approximately 3–5% of Caucasian and 15–20% of Asian populations being poor metabolisers with no CYP2C19 function.

CYP2C19 Ligands


  1. Where classes of agents are listed, there may be exceptions within the class.
Selected inducers, inhibitors and substrates of CYP2C191
Type Agent
inducers carbamazepine, norethindrone, prednisone, rifampicin
inhibitors chloramphenicol, cimetidine, fluoxetine, fluvoxamine, indomethacin, ketoconazole, lansoprazole, modafinil, omeprazole, oxcarbazepine, probenecid, ticlopidine, topiramate
substrates amitriptyline, antiepileptics (incl. diazepam, phenytoin, phenobarbital), citalopram, clomipramine, cyclophosphamide, imipramine, indomethacin, moclobemide, nelfinavir, primidone, progesterone, proguanil, propranolol, proton pump inhibitors (lansoprazole, omeprazole, pantoprazole, rabeprazole, etc), teniposide, warfarin
Notes:

See also


Cytochrome P450

 

This article is licensed under the GNU Free Documentation License. It uses material from the "CYP2C19".

Home Pageartsbusinesscomputersgameshealthhospitalshomekids & teensnewsphysiciansrecreationreferenceregionalscienceshoppingsocietysportsworld